Ads
related to: cancer gene mutations in humans list of diseases treatment drugs
Search results
Results From The WOW.Com Content Network
Lovotibeglogene autotemcel (Lyfgenia): treatment for sickle cell disease. [11] Nadofaragene firadenovec (Adstiladrin): treatment for bladder cancer [13] Obecabtagene autoleucel (Aucatzyl): treatment of acute lymphoblastic leukemia [14] [15] Onasemnogene abeparvovec (Zolgensma): AAV-based treatment for spinal muscular atrophy [16] Strimvelis ...
Human No Yes Yes Catalogue Of Somatic Mutations In Cancer (COSMIC) →: Wellcome Trust Sanger Institute, UK Mutation: No Yes Human: Yes Yes Yes cBio Cancer Genomics Portal →: Memorial Sloan-Kettering Cancer Center, United States Copy number, Mutation, Methylation, Gene Expression, miRNA Expression, Protein, Phosphorylation: No Yes Human: No ...
Oncogenomics is a sub-field of genomics that characterizes cancer-associated genes.It focuses on genomic, epigenomic and transcript alterations in cancer. Cancer is a genetic disease caused by accumulation of DNA mutations and epigenetic alterations leading to unrestrained cell proliferation and neoplasm formation.
BRCA gene mutations: The tumor suppressing BRCA genes frequently help in cancer prevention. They control how cells divide and develop and help repair DNA damage BRCA gene abnormalities, however, can the likelihood of having specific cancers is raised. Cancers BRCA1 and BRCA2 are the two BRCA recognized cancer-causing gene alterations.
Mutations in genes that regulate cell division, apoptosis (cell death), and DNA repair may result in uncontrolled cell proliferation and cancer. Cancer is fundamentally a disease of regulation of tissue growth. In order for a normal cell to transform into a cancer cell, genes that regulate cell growth and differentiation must be altered. [13]
EGFR-mutation positive non-small cell lung cancer. Skin reactions, diarrhoea, dehydration, haemorrhage, interstitial lung disease (uncommon), pancreatitis (uncommon), hepatitis (uncommon), allergy (uncommon), hepatic failure (rare), toxic epidermal necrolysis (rare) and Stevens–Johnson syndrome (rare). Imatinib: PO: Bcr-Abl kinase inhibitor.